Insider / Edwards Lifesciences Corp
BOBO DONALD E JR
CVP,Strategy/Corp Development at Edwards Lifesciences Corp
- Company
- Edwards Lifesciences Corp
- Ticker
- EW
- First filing on record
- December 10, 2025
- Latest trade on record
- May 27, 2026
- SEC filings
- EDGAR ↗
BOBO DONALD E JR, CVP,Strategy/Corp Development at Edwards Lifesciences Corp, has disclosed 30 transactions in EW since December 10, 2025: 0 purchases (0 open-market buys) and 16 sales, worth about $15.3M at the reported prices. The latest was filed May 27, 2026, 0 days after the trade.
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
In the last 12 months BOBO DONALD E JR made no purchases and 16 sales worth $12M, plus 14 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
BOBO DONALD E JR has traded 1 stock on record; the largest by dollars is EW.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
0 of 11 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 12 | 133,199 | $11.2M |
| M | Option exercise or conversion | 10 | 140,314 | $3.4M |
| F | Shares withheld for tax | 4 | 9,807 | $792K |
| A | Grant or award | 3 | 59,700 | — |
| G | Gift | 1 | 7,100 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 24 | 0 | 13 · $10.0M |
| 2025 | 6 | 0 | 3 · $1.9M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| EW | Sell S | May 27, 2026 | May 27, 2026 | 0d | 23,145 | $86 | $2.0M | indirect | Form 4 ↗ | |
| EW | Sell S | May 15, 2026 | May 18, 2026 | 3d | 8,000 | $82 | $655K | indirect | Form 4 ↗ | |
| EW | Sell S | May 15, 2026 | May 18, 2026 | 3d | 9,968 | $82 | $818K | Form 4 ↗ | ||
| EW | Option / conversion M | May 11, 2026 | May 12, 2026 | 1d | 13,457 | — | — | derivative | Form 4 ↗ | |
| EW | Sell F | May 11, 2026 | May 12, 2026 | 1d | 7,469 | $80 | $597K | Form 4 ↗ | ||
| EW | Option / conversion M | May 11, 2026 | May 12, 2026 | 1d | 13,457 | — | — | Form 4 ↗ | ||
| EW | Other A | May 7, 2026 | May 8, 2026 | 1d | 7,850 | — | — | derivative | Form 4 ↗ | |
| EW | Other A | May 7, 2026 | May 8, 2026 | 1d | 44,000 | — | — | derivative | Form 4 ↗ | |
| EW | Sell F | May 8, 2026 | May 8, 2026 | 0d | 1,038 | $83 | $86K | Form 4 ↗ | ||
| EW | Sell F | May 7, 2026 | May 8, 2026 | 1d | 831 | $83 | $69K | Form 4 ↗ | ||
| EW | Other A | May 7, 2026 | May 8, 2026 | 1d | 7,850 | — | — | Form 4 ↗ | ||
| EW | Sell F | May 3, 2026 | May 4, 2026 | 1d | 469 | $84 | $39K | Form 4 ↗ | ||
| EW | Option / conversion M | April 2, 2026 | April 2, 2026 | 0d | 22,680 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| EW | Sell S | April 2, 2026 | April 2, 2026 | 0d | 18,004 | $80 | $1.4M | 10b5-1 plan | Form 4 ↗ | |
| EW | Sell S | April 2, 2026 | April 2, 2026 | 0d | 4,676 | $81 | $377K | 10b5-1 plan | Form 4 ↗ | |
| EW | Option / conversion M | April 2, 2026 | April 2, 2026 | 0d | 22,680 | $59 | $1.3M | 10b5-1 plan | Form 4 ↗ | |
| EW | Option / conversion M | March 2, 2026 | March 2, 2026 | 0d | 11,340 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| EW | Sell S | March 2, 2026 | March 2, 2026 | 0d | 11,340 | $86 | $974K | 10b5-1 plan | Form 4 ↗ | |
| EW | Option / conversion M | March 2, 2026 | March 2, 2026 | 0d | 11,340 | $59 | $672K | 10b5-1 plan | Form 4 ↗ | |
| EW | Sell S | February 25, 2026 | February 26, 2026 | 1d | 24,000 | $84 | $2.0M | Form 4 ↗ | ||
| EW | Option / conversion M | January 6, 2026 | January 6, 2026 | 0d | 11,340 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| EW | Sell S | January 6, 2026 | January 6, 2026 | 0d | 8,708 | $86 | $749K | 10b5-1 plan | Form 4 ↗ | |
| EW | Sell S | January 6, 2026 | January 6, 2026 | 0d | 2,632 | $85 | $223K | 10b5-1 plan | Form 4 ↗ | |
| EW | Option / conversion M | January 6, 2026 | January 6, 2026 | 0d | 11,340 | $59 | $672K | 10b5-1 plan | Form 4 ↗ | |
| EW | Other G | December 12, 2025 | December 12, 2025 | 0d | 7,100 | — | — | Form 4 ↗ | ||
| EW | Sell S | December 12, 2025 | December 12, 2025 | 0d | 5,900 | $84 | $494K | Form 4 ↗ | ||
| EW | Sell S | December 12, 2025 | December 12, 2025 | 0d | 5,486 | $84 | $460K | Form 4 ↗ | ||
| EW | Option / conversion M | December 10, 2025 | December 10, 2025 | 0d | 11,340 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| EW | Sell S | December 10, 2025 | December 10, 2025 | 0d | 11,340 | $84 | $951K | 10b5-1 plan | Form 4 ↗ | |
| EW | Option / conversion M | December 10, 2025 | December 10, 2025 | 0d | 11,340 | $59 | $672K | 10b5-1 plan | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 27, 2026 | Form 4 | 0001225208-26-005610 | 1 | published | EDGAR ↗ |
| May 18, 2026 | Form 4 | 0001225208-26-005463 | 2 | published | EDGAR ↗ |
| May 12, 2026 | Form 4 | 0001225208-26-005171 | 3 | published | EDGAR ↗ |
| May 8, 2026 | Form 4 | 0001225208-26-005048 | 5 | published | EDGAR ↗ |
| May 4, 2026 | Form 4 | 0001225208-26-004907 | 1 | published | EDGAR ↗ |
| April 2, 2026 | Form 4 | 0001225208-26-004249 | 4 | published | EDGAR ↗ |
| March 2, 2026 | Form 4 | 0001225208-26-002878 | 3 | published | EDGAR ↗ |
| February 26, 2026 | Form 4 | 0001225208-26-002711 | 1 | published | EDGAR ↗ |
| January 6, 2026 | Form 4 | 0001225208-26-000378 | 4 | published | EDGAR ↗ |
| December 12, 2025 | Form 4 | 0001225208-25-009935 | 3 | published | EDGAR ↗ |
| December 10, 2025 | Form 4 | 0001225208-25-009841 | 3 | published | EDGAR ↗ |
Other insiders at Edwards Lifesciences Corp
- Lippis Daniel J. CVP, JAPAC 52 rows
- Zovighian Bernard J CEO 35 rows
- Ullem Scott B. Director 31 rows
- Mistras Theodora Chief Financial Officer 23 rows
- Chopra Daveen CVP, TMTT & Surgical 16 rows
- Markowitz Wayne CVP, JAPAC 14 rows
- Dahl Andrew M. SVP, Corporate Controller 9 rows
- Bruls Annette CVP, EMEACLA 6 rows
- Feinberg David T Director 5 rows
- GALLAHUE KIERAN Director 2 rows
Everyone on file, with contracts and lobbying under the company's name: Edwards Lifesciences Corp.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 11 | 30 | December 10, 2025 | May 27, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.